Update 1 March 2024

Below is the updated document with appointments and update timeline to 1 March 2024.

Original text

Pharma Value developed with Nomos a background document with the update of the appointments of members that will make up the new CSE (Scientific and Economic Commission), of the administrative and technical-scientific directorsof the President reconfirmed and the 2 members of the CDA of its competence, on the basis of the amendments requested by the State-Regions Conference and the Council of State.

We also carried out a focus on the characteristics of the members with regard to gender, profession, region of origin.

L'target is to offer one useful tool for orientation in AIFA's reorganisation activities.

Reflection is needed on the Agency's mission and the relative suitability of the new apparatus to govern Italian pharmaceutical expenditure.

The latest data from AIFA's Osmed Report indicate total national expenditure (public and private) of EUR 34.1 billion in 2022, an increase of 6.0% compared to 2021. A growth trend that is also being confirmed for 2023. The value of total pharmaceutical expenditure added to out-of-pocket expenditure (about 40 billion) represents more than 4% of the national GDP.

The hope is that the new AIFA will be adequate to manage these numbers and to enhance a sector that is often governed only as a source of revenue or expenditure and not as a resource in which to invest for the country's economic growth.

Nomos and Pharma Value undertake to update the document with legal-institutional news, information and reflections on the basis of forthcoming developments relating in particular to the approval of the New AIFA Regulation by the CDA.

If you want to learn more about the AIFA Governance Reform in its various approval steps, read our article: Special Commission Update No. 3 - Towards the reform of the governance of the Italian Medicines Agency and the Single Commission: where are we?